252
Participants
Start Date
July 3, 2023
Primary Completion Date
September 18, 2025
Study Completion Date
September 18, 2025
ENX-102
Selective GABA-A alpha2,3,5 positive allosteric modulator
Placebo
Placebo
Richmond Behavioral Associates, Staten Island
SPRI Clinical Trials, LLC, Brooklyn
Neurobehavioral Research, Cedarhurst
CenExel iResearch, LLC, Savannah
Clinical Neuroscience Solutions, Inc., Jacksonville
Accel Research Sites Network - Maitland CRU, Maitland
Clinical Neuroscience Solutions, Inc., Orlando
Accel Research Sites Network - Lakeland CRU, Lakeland
Vertex Clinical Research, Clermont
Clinical Neuroscience Solutions, Inc., Memphis
Precise Research Centres, Flowood
Collective Medical Research, Overland Park
Aim Trials, Plano
FutureSearch Trials of Dallas, Dallas
Grayline Research Center, Wichita Falls
Baylor College of Medicine, Houston
Austin Clinical Trials Partners, Austin
Mountain View Clinical Research, Denver
Alpine Research Organization, Clinton
IMA Clinical Research Phoenix, Phoenix
IMA Clinical Research, Las Vegas
NRC Research Institute, Los Angeles
Alliance Research, Long Beach
California Neuroscience Research, LLC, Sherman Oaks
Pacific Clinical Research Management Group, Upland
Excell Research, Inc., Oceanside
Sun Valley Research Center, Imperial
Anderson Clinical Research, Redlands
Collaborative Neuroscience Research, LLC (CNS), Garden Grove
Sunwise Clinical Research, Walnut Creek
Core Clinical Research, Everett
Boston Clinical Trials, Boston
Lead Sponsor
Engrail Therapeutics INC
INDUSTRY